Oxford Drug Design secures £2.2M to develop drugs against cancer using AI — TFN

Oxford Drug Design, a biotechnology company specializing in AI-powered drug discovery for cancer treatment, has secured £2.2 million in funding. The round was led by existing investors ACF Investors, o2h Ventures, Meltwind Advisory, and US-based R42 Group, along with numerous angel investors. This brings Oxford Drug Design's total funding to over £10 million. The funding will be used to validate its innovative approach to cancer through a proof-of-concept study, commercialize its AI platform to pharmaceutical and biotechnology companies, and expand operations ahead of a Series A round later this year.

Oxford Drug Design Raises £2.2 Million to Advance AI-Driven Cancer Therapeutics

Oxford Drug Design is a biotechnology company developing drugs against cancer using AI. The company is a spin-out from the Oxford University Chemistry Department by Professor Graham Richards OBE FRS and has developed a proprietary AI platform for drug discovery.

A biotechnology company developing drugs against cancer using AI, spun out from the Oxford University Chemistry Department.

3 years ago

Oxford Drug Design Raises £2.2 Million to Advance AI-Driven Cancer Therapeutics

Covered on